This Japanese company has an oligonucleotide synthesis technology which was developed based on their proprietary raw materials.
The advantage is that they resolved many issues the conventional oligonucleotide synthesis methods had.
Oligonucleotide synthesis applies in both the pharma industry and academia research sectors.
The company seeks EU partners who can help them represent, distribute, and manufacture products produced with this synthesis technology.
Please see the company pdf for more details.
The EU-Japan Centre currently produces 5 newsletters :
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.
The EU-Japan Centre’s activities are subject to the allocation of a Grant Agreement by the European Commission for 2024-2026